First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study.
Nan Lyu, Qianqian Wang, Kuirong Jiang, Dong Xu, Yang Wu, Kai Zhang, Jishu Wei, Jianmin Chen, Feng Guo, Zipeng Lu, Bin Xiao, Guosheng Chen, Junli Wu, Wentao Gao, Yuqi Wang, Fufeng Wang, Min Tu
{"title":"First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study.","authors":"Nan Lyu, Qianqian Wang, Kuirong Jiang, Dong Xu, Yang Wu, Kai Zhang, Jishu Wei, Jianmin Chen, Feng Guo, Zipeng Lu, Bin Xiao, Guosheng Chen, Junli Wu, Wentao Gao, Yuqi Wang, Fufeng Wang, Min Tu","doi":"10.1093/gastro/goag034","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is one of the most lethal malignancies, with limited therapeutic options. In this exploratory trial, we aimed to evaluate the efficacy and safety of nanoparticle polymeric micellar paclitaxel (pm-Pac) combined with gemcitabine as first-line treatment for metastatic pancreatic cancer (mPC).</p><p><strong>Methods: </strong>Twenty-one patients with histologically or cytologically confirmed mPC were enrolled in this study. The primary endpoint was progression-free survival (PFS). Meanwhile, the secondary endpoints included the objective response rate (ORR), overall survival, disease control rate (DCR), duration of response (DOR), and safety of combination therapy.</p><p><strong>Results: </strong>The median PFS was 7.4 months (95% confidence interval [CI]: 5.4-9.4 months). The ORR and DCR were 52.4% (95% CI: 29.1%-75.7%) and 95.2% (95% CI: 85.3%-100%), respectively. Amongst patients who achieved partial response, the median DOR was 4.8 months (95% CI: 1.5-8.1 months). No treatment-related deaths were reported. Grade 3-4 adverse events (AEs) occurred in 81.0% of patients, with increased γ-glutamyltransferase levels (38.1%), neutropenia (33.3%), and leukocytopenia (28.6%) being the most frequent AEs. Low SERPINB3 and SERPINB4 expression was correlated with prolonged PFS, accompanied by the significant downregulation of gene sets involved in DNA replication, nonsense-mediated mRNA decay, and protein translation in long-PFS tumours. Tumour immune microenvironment analysis revealed that patients with short PFS had increased levels of common lymphoid progenitors and decreased populations of mature B and T lymphocytes.</p><p><strong>Conclusions: </strong>The combination of pm-Pac and gemcitabine as first-line therapy for mPC exhibited favourable tolerability and clinical efficacy. However, larger randomized-controlled trials are needed to validate these preliminary findings.</p><p><strong>Trial registration: </strong>www.chictr.org.cn, ChiCTR2300078861.</p>","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag034"},"PeriodicalIF":4.2000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13132657/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology Report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/gastro/goag034","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Pancreatic cancer is one of the most lethal malignancies, with limited therapeutic options. In this exploratory trial, we aimed to evaluate the efficacy and safety of nanoparticle polymeric micellar paclitaxel (pm-Pac) combined with gemcitabine as first-line treatment for metastatic pancreatic cancer (mPC).
Methods: Twenty-one patients with histologically or cytologically confirmed mPC were enrolled in this study. The primary endpoint was progression-free survival (PFS). Meanwhile, the secondary endpoints included the objective response rate (ORR), overall survival, disease control rate (DCR), duration of response (DOR), and safety of combination therapy.
Results: The median PFS was 7.4 months (95% confidence interval [CI]: 5.4-9.4 months). The ORR and DCR were 52.4% (95% CI: 29.1%-75.7%) and 95.2% (95% CI: 85.3%-100%), respectively. Amongst patients who achieved partial response, the median DOR was 4.8 months (95% CI: 1.5-8.1 months). No treatment-related deaths were reported. Grade 3-4 adverse events (AEs) occurred in 81.0% of patients, with increased γ-glutamyltransferase levels (38.1%), neutropenia (33.3%), and leukocytopenia (28.6%) being the most frequent AEs. Low SERPINB3 and SERPINB4 expression was correlated with prolonged PFS, accompanied by the significant downregulation of gene sets involved in DNA replication, nonsense-mediated mRNA decay, and protein translation in long-PFS tumours. Tumour immune microenvironment analysis revealed that patients with short PFS had increased levels of common lymphoid progenitors and decreased populations of mature B and T lymphocytes.
Conclusions: The combination of pm-Pac and gemcitabine as first-line therapy for mPC exhibited favourable tolerability and clinical efficacy. However, larger randomized-controlled trials are needed to validate these preliminary findings.
期刊介绍：
Gastroenterology Report is an international fully open access (OA) online only journal, covering all areas related to gastrointestinal sciences, including studies of the alimentary tract, liver, biliary, pancreas, enteral nutrition and related fields. The journal aims to publish high quality research articles on both basic and clinical gastroenterology, authoritative reviews that bring together new advances in the field, as well as commentaries and highlight pieces that provide expert analysis of topical issues.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
